COVID-19 Vaccine

Quick Reference Guide for Healthcare Professionals



The table below provides basic information on the proper storage, preparation, and administration of the currently authorized COVID-19 vaccine products in the United States. For additional information and detailed clinical guidance go to the manufacturers' website and CDC's webpages listed.

Interfaction Independence of particulation of the second sec			Pfizer-BioNTech	Moderna	Janssen
Bit Notice Instruction Construction Construction Construction Construction Instruction Notification Notification <th></th> <th></th> <th>response/coronavirus-disease-2019-covid-19/</th> <th>response/coronavirus-disease-2019-covid-19/</th> <th></th>			response/coronavirus-disease-2019-covid-19/	response/coronavirus-disease-2019-covid-19/	
O Operational State Note: Note: 1 and	E N E				
File File Scale of the Scale Scal		Contact	Medical information: 800-438-1985		
Display Display <t< th=""><th>How Supplied</th><th>Multidose vial: 6 doses</th><th>Multidose vial: Maximum of 15 doses</th><th>Multidose vial: 5 doses</th></t<>		How Supplied	Multidose vial: 6 doses	Multidose vial: Maximum of 15 doses	Multidose vial: 5 doses
Non-springer Beneric Function Non-springer Section 10 (117 met 2019) and 10 (118 heat 1000) Non-springer Section 10 (118 heat 2019) and 1000 heat 2010 heat 1000 heat 2010 heat 1000 heat 2010 heat 2010 heat 2010 heat 1000 heat 2010 heat 2010 heat 2010 heat 1000 heat 2010 heat 2010 heat 2010 heat 1000 heat 2010 heat 2010 heat 2010 heat 2010 heat 2010 heat 2010 heat 2010 heat 2010 heat 2010 heat 2010 heat 2010 heat 201		Diluent		None	None
Biospectrum Number of the second	ANDLI	Temperatures:	-80°C and -60°C (-112°F and -76°F) until the expiration date -25°C and -15°C (-13°F and 5°F) for up to 2 weeks	-50°C and -15°C (-58°F and 5°F) until the expiration date 2°C and 8°C (36°F and 46°F) for up to 30 days	2°C and 8°C (36°F and 46°F)
Ope Ope Operation Operation<	E &	Temperatures:	2°C to 25°C (36°F to 77°F) for up to 6 hours	2°C and 25°C (36°F and 77°F) for up to 12 hours	2°C and 8°C (36°F and 46°F) for up to 6 hours 9°C and 25°C (47°F and 77°F) for up to 2 hours
Interaction Retroaction Retroaction Retroaction Retroaction Version 22.000 rand 27.01 for up to 1 hours. 22.000 rand 27.01 for up to 1 hours. 24.000 rand 27.01 for up to 1 hours. Version Age Indications 10.000 rand 20.000 rand 27.01 for up to 1 hours. 10.900 rand 20.000 rand 27.000 rand 27.00	TOR	Temperatures:	-80°C and -60°C (-112°F and -76°F) -25°C and -15°C (-13°F and 5°F)	-50°C and -15°C (-58°F and 5°F) 2°C and 8°C (36°F and 46°F) for up to 12 cumulative	
Image indication Signam of any Signam Office CONNEXATY is and	S	Temperatures*:			
Mge indication Mge year, drog and addreg (COMBINITY) Injustice of adjacent operation (COMBINITY) Injustice of adjacent operation (COMBINITY) Primary Schedul Mge year, drog and adjacent (COMBINITY) Construction (COMBINITY) Injustice of adjacent operation (COMBINITY) Primary Schedul Mge year, drog and adjacent (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Mge was and adjacent operation (COMBINITY) Primary Schedul Massessment (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Mge in addition (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Mode in Advacent (Mol Injection (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Mode in Advacent (Mol Injection (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Mode in Advacent (Mol Injection (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Construction (COMBINITY) Mode in Advacent (Mol Injection (COMBINITY) Construction (COMBINITY) Constructin (COMBINITY) Constructin (COMBINITY)		Type of Vaccine	mRNA	mRNA	Viral vector
Primary Schedul Pointing Schedul Boolset Name Boolset Schedul Boolset Schedul Idea VIDUATION Absolute Absolute Schedul Absolute Abs		Age Indications		18 years of age and older	18 years of age and older
Notice Topset Participation of the section of the sectin sectin of the section of the section of the section o		Primary Schedule⁺	BioNTech vaccine (An additional [3rd] dose for moderately to severely		1 dose
Dosage 0.3 mL 0.5 mL 0.5 mL 0.5 mL Needle Gauge/ Instant 12 through 18 years of age: 22-25 gauge, 1 = 119" 22-25 gauge, 1 = 114" 22-25 gauge, 1 = 114" </th <th></th> <th>Booster Doses</th> <th colspan="3">A booster dose at least 6 months after the primary series should be given for: • People aged 65 years and older • Residents aged 18 years and older in long-term care settings • People aged 50-64 with underlying medical conditions (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html) A booster dose at least 6 months after the primary series may be given based on their individual benefits and risks for: • People aged 18-49 years with underlying medical conditions (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)</th>		Booster Doses	A booster dose at least 6 months after the primary series should be given for: • People aged 65 years and older • Residents aged 18 years and older in long-term care settings • People aged 50-64 with underlying medical conditions (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html) A booster dose at least 6 months after the primary series may be given based on their individual benefits and risks for: • People aged 18-49 years with underlying medical conditions (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)		
Needle Gauge' 12 through 18 years of age: 22-25 gauge, 1'' 22-25 gauge, 1 = 11s'' 22-25 gauge, 1 = 11s'' Needle Gauge' Intranuscular (M) injection Intranuscular (M) injection Intranuscular (M) injection Site Delioid Delioid Delioid Delioid Thawing Frozen Vaccine Retween: 2C and 8'C (B6'T and 46'T) or floom temperature up to 25'C C' and 8'C (B6'T and 46'T) or floom temperature up to 25'C C' and 8'C (B6'T and 46'T) or floom temperature up to 25'C C' and 8'C (B6'T and 46'T) or floom temperature up to 25'C C' and 8'C (B6'T and 46'T) or floom temperature up to 25'C C' and 8'C (B6'T and 46'T) or floom temperature up to 25'C C' and 8'C (B6'T and 46'T) or floom temperature up to 25'C C' and 8'C (B6'T and 46'T) or floom temperature up to 25'C C' and 8'C (B6'T and 46'T) or floom temperature up to 25'C T'/ TD floo NOT mix with any diluent. N/A Mixing Vaccine Mix vaccine with 1.8 m.t of 0.9% sodium chloride (preservative - sovernal saline). to NOT mix with any diluent. De NOT mix with any diluent. Contraindications/ Precautions Contraindication to an mRNA COVID-19 vaccine (Moderna or PIzer Sel)NFech may be able to receive an mRNA COVID-19 vaccine (see footnote). ¹ Precautions *Most people determined to have a precaution to a COVID-19 vaccine with ease of which is a vaccine component, but for whom it is unknown which component elicited he immediate allergic reaction to a vaccine or injectable therapy (ie., intramuscular, intrawenous, or sub-Cutane component, but for whom it is unknown which component elicited he immediate allergic reaction to a vaccine or injectable therapy (ie., intramuscular, intrawenous, or sub-Cutane com	7	Dosage			
Route Intramuscular (IM) injection Intramuscular (IM) injection Intramuscular (IM) injection Visite Detoid Detoid Detoid Detoid Thawing Frozen Vaccine Retween: (777 F) Do NOT refreeze thawd vaccine. Retween: (777 F) Do NOT refreeze thawd vaccine. N/A Mixing Vaccine Mix vacine with 1 & IL of 0.9% sodium chloride (preservative the, normal salle). Do NOT mix with any diluent. Do NOT mix with any diluent. Owner Contraindications - Severa allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine Contraindications - Severa allergic reaction (and anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine Do NOT mix with any diluent. Precautions Precautions Precautions Precautions Interduce allergic reaction to a assen COVID-19 vaccine with a set or creative and should be administered vaccine. Interduce allergic reaction to a ot COVID-19 vaccine at their appointment can and should be administered vaccine. Precautions Precautions Precaution to a mixediar allergic reaction to a vaccine or injectable therapy (i.e., intramuscular, intravenous, or, sub-utaneous vaccine or therapies) This includes people with a sector to a vaccine or injectable therapy (i.e., intramuscular, intravenous, or, sub-utaneous vaccine or therapies) Precautions This includes people with a bistory of an	0	Needle Gauge/		22–25 gauge, 1 – 1½"	22–25 gauge, 1 – 1½"
File Deltoid Deltoid Deltoid Naming Frozen Review: Betwee:: Could SC (36F and 46F) or Room temperature up to 25C (7F) Do NOT refreze thawed vaccine. Betwee:: Crant SC (36F and 46F) or 8°C to 25C (46F to 7F) Do NOT refreze thawed vaccine. N/A Nixing Vaccine Mix witche with 1.8 ml of 0.9% sodium chloride (preservitive) Do NOT mix with any diluent. Do NOT mix with any diluent. Verse Feereal target reaction (e.g., anaphylaxis) after a previous dose or knowned) (20/DI-19 vaccine COVID-19 vaccine Severe allergic reaction of any severity to a previous dose or knowned (allengosed) allergy to a component of the COVID-19 vaccine (20/DI-19 vaccine) Severe allergic reaction of any severity to a previous dose or knowned (allengosed) allergy to a component of the COVID-19 vaccine (Moderna or PRIze-BioNTech) may be able to receive an RRA COVID-19 vaccine (Moderna or PRIze-BioNTech) may be able to receive an RRA COVID-19 vaccine (see footnote). ⁵ Precautions Fereautions Nost people determined to bare a precaution to a COVID-19 vaccine at their appointment can and should be administered vaccine. Severe allergic reaction to any ORVID-19 vaccine (word ministrate nous, or ubucci vaccine. * Nost people determined to bare a precaution to a COVID-19 vaccine or injectable therapy (i.e., intramuscula, intravenous, or ubucci vaccine. Severe allergic reaction to any ORVID-19 vaccine severe autilities or vaccine component, but for whom it is unknown which component elicited the immediate allergic reaction to any ORVID-19 vaccine severe autilities or vaccine or onjectable therapy (i.e., intramuscula, intravenous, ore of whichet). Precautions <t< th=""><th>A</th><th>_</th><th>Intramuscular (IM) injection</th><th>Intramuscular (IM) injection</th><th>Intramuscular (IM) injection</th></t<>	A	_	Intramuscular (IM) injection	Intramuscular (IM) injection	Intramuscular (IM) injection
Image: Processing Procesprependent Processing Processing Processing Processing Processing		Site	Deltoid	Deltoid	Deltoid
Mixing Vaccine free, normal saline). Do NOT mix with any diluent. Do NOT mix with any diluent. 00 Not: free, normal saline). Contraindications - Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the cOVID-19 vaccine - Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the vaccine Not: Persons who have a contraindication to an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 vaccine (see footnote). ⁵ Persons who have a contraindication to an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 vaccine (see footnote). ⁵ Persons who have a contraindication to an severity to a previous dose or known (diagnosed) allergy to a component of the vaccine. - History of an immediate allergic reaction to a OVID-19 vaccine at their appointment can and should be administered vaccine. Precautions Precautions * Most people determined to have a precaution to a Vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies) > This includes people with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is a vaccine component, but for whom it is unknown which considerations for Use of COVID-19 vaccines have a precaution to Janssen COVID-19 Vaccine, and vice versa. (see footnote). ⁵ Post-Vaccination 30 minutes: People with a history of an immediate allergic reaction of any severity to a vaccine or injectable therapy, contraindication to a different type of COVID-19 vacci	N	-	2°C and 8°C (36°F and 46°F) or Room temperature up to 25°C	2°C and 8°C (36°F and 46°F) or 8°C to 25°C (46°F to	N/A
Version Contraindications Version Severe allergic reaction (e.g., anaphylaxis) after a previous dose or known (diagnosed) allergy to a component of the vaccine (COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 vaccine (See footnote). ⁵ Persons who have a contraindication to an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 vaccine (see footnote). ⁵ Persons who have a contraindication to an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 vaccine (see footnote). ⁵ Precautions Precautions * Most people determined to have a precaution to a COVID-19 vaccine at their appointment can and should be administered vaccine. * History of an immediate allergic reaction to a vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies) * This includes people with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is a vaccine component, but for whom it is unknown which component elicited the immediate allergic reaction. * People with a contraindication to mRNA COVID-19 Vaccines currently Approved or Authorized in the United States http://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html * Obst-Vaccination Oninutes: People with a history of an immediate allergic reaction of any severity to a vaccine or injectable therapy. contraindication to a different type of COVID-19 vaccine, or history of an immediate allergic reaction of any severity to a vaccine or injectable therapy. contraindication to	۵	Mixing Vaccine		Do NOT mix with any diluent.	Do NOT mix with any diluent.
 People with a contraindication to mRNA COVID-19 vaccines have a precaution to Janssen COVID-19 Vaccine, and vice versa. (see footnote).⁵ Moderate to severe acute illness See Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States http://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html Post-Vaccination Observation Most Common Adverse Events Injection site: pain, swelling, redness Systemic: fatigue, headache, muscle pain, chills, fever, joint pain 	ACCINE		 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine Immediate allergic reaction[‡] of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine Note: Persons who have a contraindication to an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 vaccine (see footnote).[§] Persons who have a contraindication to Janssen COVID-19 Vaccine may be able to receive an mRNA COVID-19 vaccine (see footnote).[§] Precautions Most people determined to have a precaution to a COVID-19 vaccine at their appointment can and should be administered vaccine. History of an immediate allergic reaction[‡] to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies) This includes people with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is a vaccine component, but for whom it is unknown which 		
Post-Vaccination Observation anaphylaxis due to any cause. 15 minutes: All other persons 15 minutes: All other persons Most Common Adverse Events Injection site: pain, swelling, redness Systemic: fatigue, headache, muscle pain, chills, fever, joint pain Systemic: fatigue, headache, muscle pain, chills, fever, joint pain			 People with a contraindication to mRNA COVID-19 vaccines have a precaution to Janssen COVID-19 Vaccine, and vice versa. (see footnote).[§] Moderate to severe acute illness See Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States http://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html 		
Most Common Adverse Events Systemic: fatigue, headache, muscle pain, chills, fever, joint pain			anaphylaxis due to any cause.		
nausea, joint pain			Injection site: pain, swelling, redness Systemic : fatigue, headache, muscle pain, chills, fever, joint pain	Systemic: fatigue, headache, muscle pain, chills, fever,	Injection site: pain, redness, swelling Systemic: fatigue, headache, muscle pain, nausea, fever

*CDC recommends transporting vaccine at refrigerated or frozen temperatures.

[†]COVID-19 vaccines and other vaccines may be administered without regard to timing, including coadministration on the same day. When deciding if to administer COVID-19 vaccines and other vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable diseases (e.g., during an outbreak), and the reactogenicity profile of the vaccines. [†]For the purpose of this guidance, an immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms, such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

⁵Consider consultation with an allergist-immunologist to help determine if the patient can safely receive vaccination. Healthcare providers and health departments may also request a consultation from the Clinical Immunization Safety Assessment Project <u>https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html</u>. Vaccination of these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions.

- People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to Janssen COVID-19 vaccination. People who have previously received an mRNA COVID-19 vaccine dose but have a contraindication to a second dose should wait at least 28 days to receive Janssen COVID-19 Vaccine.
- People with a contraindication to Janssen COVID-19 Vaccine (including due to a known polysorbate allergy) have a precaution to mRNA COVID-19 vaccination.